GlassScriptPhysician profile
Anthony W Le
NPI 1720185291
$1,418.45
in general payments reported to CMS, 2019-2025
33 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $128 · 2021: $138 · 2022: $286 · 2023: $304 · 2024: $144 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $136.56 | 2022-2024 | Ingrezza, Ongentys |
| Abbvie INC. | $94.28 | 2023-2025 | |
| Tactile Systems Technology INC | $82.59 | 2019-2022 | |
| Nevro Corp. | $81.99 | 2023 | Senza |
| Amgen INC. | $81.65 | 2024-2025 | Krystexxa |
| Zimmer Biomet Holdings, INC. | $77.93 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $70.04 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.69 | 2022 | |
| Paratek Pharmaceuticals, INC. | $65.63 | 2023 | Nuzyra |
| Ermi LLC | $54.50 | 2019 | |
| Orthofix Medical, INC. | $51.58 | 2019 | |
| Treace Medical Concepts, INC. | $47.11 | 2022 | |
| Zyla Life Sciences, INC. | $44.79 | 2019 | |
| Bioventus LLC | $40.80 | 2019 | |
| Micromed INC | $40.15 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $38.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.01 | 2021-2023 | Trintellix |
| Emd Serono, INC. | $34.49 | 2024 | |
| Banner Life Sciences, LLC | $26.55 | 2024 | |
| Smith+Nephew, INC. | $25.77 | 2025 | Grafix Pl |
| Novartis Pharmaceuticals Corporation | $23.04 | 2019 | |
| Mdd US Operations, LLC | $22.53 | 2023 | Apokyn |
| Alnylam Pharmaceuticals INC. | $20.96 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.56 | 2019 | |
| Csl Behring | $18.88 | 2020 | |
| Linvatec Corporation | $18.16 | 2025 | 5ms |
| Stryker Corporation | $16.11 | 2024 | Easyfuse |
| Assertio Therapeutics, INC. | $15.34 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.43 | 2021 | |
| Acorda Therapeutics, INC | $13.00 | 2022 | |
| Angiodynamics, INC. | $12.87 | 2022 | |
| Medartis INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.